Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes

Cancer Gene Therapy

Volumn 19, Issue 4, 2012, Pages 292-298

  Kanzaki, A ^a   Kasuya, H ^a   Yamamura, K ^a   Sahin, T T ^a   Nomura, N ^a   Shikano, T ^a   Shirota, T ^a   Tan, G ^a   Fukuda, S ^a   Misawa, M ^a   Nishikawa, Y ^a   Yamada, S ^a   Fujii, T ^a   Sugimoto, H ^a   Nomoto, S ^a   Takeda, S ^a   Kodera, Y ^a   Nakao, A ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

colon cancer; intravenous therapy; oncolytic herpes virus; peritoneal dissemination; tumor antigen specific lymphocytes; virus systemic delivery

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ONCOLYTIC HERPES VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG EFFICACY; HERPES SIMPLEX VIRUS 1; LYMPHOCYTE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; SYSTEMIC THERAPY; TUMOR IMMUNITY; VIRUS IMMUNITY; VIRUS MUTANT;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE; CERCOPITHECUS AETHIOPS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HERPESVIRUS 1, HUMAN; HUMANS; LYMPHOCYTES; MICE; MICE, INBRED BALB C; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PERITONEAL NEOPLASMS;

HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; MUS; SIMPLEXVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84858706596     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.91     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243: 212-222. (Pubitemid 43185440)
3. Kerscher A, Esquivel J. Current status and future directions: management of colon cancer with peritoneal dissemination. Future Oncol 2005; 4: 671-679.
4. Gómez Portilla A, Cendoya I, López de Tejada I, Olabarría I, Martínez de Lecea C, Magrach L et al. Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update]. Rev Esp Enferm Dig 2005; 97: 716-737. (Pubitemid 44323959)
5. Nomura N, Kasuya H, Watanabe I, Shikano T, Shirota T, Misawa M et al. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases. Cancer Chemother Pharmacol 2009; 63: 321-330.
6. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856. (Pubitemid 121000529)
7. Kasuya H, Takeda S, Shimoyama S, Shikano T, Nomura N, Kanazumi N et al. Oncolytic virus therapy-foreword. Curr Cancer Drug Targets 2007; 7: 123-125.
8. Hamid O, Varterasian ML, Wadler S. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-1504. (Pubitemid 46594102)
9. Makower D, Rozenblit A, Kaufman H. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 2003; 9: 693-702. (Pubitemid 36182602)
10. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002; 1: 2251-2266. (Pubitemid 34441652)
11. Lorence RM, Pecora AL, Major PP, Hotte SJ, Laurie SA, Roberts MS et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 2003; 5: 618-624. (Pubitemid 38094433)
12. Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T et al. Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol 2004; 15: 988-989. (Pubitemid 39004359)
13. Markert JM, Medlock MD, Rabkin SD. Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867-874. (Pubitemid 30303584)
14. Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004; 11: 1648-1658. (Pubitemid 39530101)
15. Fong Y, Kim T, Bhargava A, Schwartz L, Brown K, Brody L et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2008; 17: 389-394.
16. Tilstone C. Virotherapy paves the way for new cancer treatment. Lancet Oncol 2004; 5: 136. (Pubitemid 38262831)
17. Deng W, Jia J. Endothelial progenitor cells as cellular vehicles to deliver oncolytic virus therapies to metastatic tumors: the 'Trojan horse' approach. Med Hypotheses 2007; 70: 842-844. (Pubitemid 351318076)
18. Kulu Y, Dorfman JD, Kuruppu D, Fuchs BC, Goodwin JM, Fujii T et al. Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther 2008; 16: 291-297.
19. Fisher K. Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr Opin Mol Ther 2006; 8: 301-313. (Pubitemid 44256364)
20. Power AT, Bell JC. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 2007; 15: 660-665. (Pubitemid 46431985)
21. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 2007; 14: 324-333. (Pubitemid 46231926)
22. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006; 311: 1780-1784.
23. Qiao J,Wang H, Kottke T, DiazRM,Willmon C, Hudacek A et al. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther 2008; 15: 604-616.
24. Yotnda P, Savoldo B, Charlet-Berguerand N, Rooney C, Brenner M. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood 2004; 104: 2272-2280. (Pubitemid 39331823)
25. Crittenden M, Gough M, Chester J, Kottke T, Thompson J, Ruchatz A et al. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res 2003; 63: 3173-3180. (Pubitemid 36735869)
26. Chester J, Ruchatz A, Gough M, Crittenden M, Chong H, Cosset FL et al. Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol 2002; 20: 256-263. (Pubitemid 34205418)
27. Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005; 11: 1073-1081. (Pubitemid 41486829)
28. Kottke T, Qiao J, Diaz RM, Ahmed A, Vroman B, Thompson J et al. The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles. Gene Ther 2006; 13: 1166-1177. (Pubitemid 44084075)
29. Thanarajasingam U, Sanz L, Diaz R, Qiao J, Sanchez-Perez L, Kottke T et al. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res 2007; 67: 300-308. (Pubitemid 46142788)
30. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675. (Pubitemid 37328821)
31. Chang AE, Shu S. Current status of adoptive immunotherapy of cancer. Crit Rev Oncol Hematol 1996; 22: 213-228. (Pubitemid 26171923)
32. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854. (Pubitemid 35231542)
33. PizzatoM, Blair ED, FlingM, Kopf J, Tomassetti A, Weiss RA et al. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. Gene Ther 2001; 8: 1088-1096. (Pubitemid 32962706)
34. Harrington K, Alvarez-Vallina L, Crittenden M, Gough M, Chong H, Diaz RM et al. Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther 2002; 13: 1263-1280. (Pubitemid 35034507)
35. Shikano T, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M et al. High Therapeutic Potential for Systemic Delivery of a Liposome-conjugated Herpes Simplex Virus. Curr Cancer Drug Targets 2011; 11: 111-122.
36. Eshun FK, Currier MA, Gillespie RA, Fitzpatrick JL, Baird WH, Cripe TP. VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy. Gene Ther 2010; 17: 922-929.
37. Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004; 15: 821-831. (Pubitemid 39244837)
38. Watanabe D, Goshima F, Mori I, Tamada Y, Matsumoto Y, Nishiyama Y. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci 2008; 50: 185-196.
39. Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther 2009; 17: 1626-1636.
40. Fishman M. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther 2009; 9: 1565-1575.
41. Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010; 101: 433-439.
42. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007; 67: 2840-2848. (Pubitemid 46548974)
43. Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008; 14: 7358-7366.
44. Li H, Zhang X. Oncolytic HSV as a vector in cancer immunotherapy. Methods Mol Biol 2010; 651: 279-290.
45. Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther 2009; 16: 689-699.